Financial Data and Key Metrics Changes - Fourth quarter revenue was $4.2 million, bringing full year 2025 revenue to $16.6 million, representing 17% year-over-year growth [4][27] - Total revenue for the fourth quarter of 2025 increased by 5% compared to $4 million in the fourth quarter of 2024, primarily due to higher product revenue [24] - Net loss for the fourth quarter of 2025 was $16 million, compared to $21.7 million in the fourth quarter of 2024 [26] Business Line Data and Key Metrics Changes - Product revenue for the fourth quarter of 2025 was $2.8 million, consisting of sales of Proteograph instruments and consumable kits [24] - Consumable kit volume increased by approximately 69% year-over-year, demonstrating increasing utilization of technology [28] - Total gross profit for the full year 2025 was $8.5 million, representing a gross margin of 51%, compared to $7.1 million in 2024 [30] Market Data and Key Metrics Changes - The installed base of instruments as of year-end 2025 was 82 instruments, representing a 67% increase from 49 at the end of 2024 [29] - Approximately 60% of the instruments installed in 2025 were part of the Strategic Instrument Placement program [21] - Cumulative publications nearly doubled from 36 at the end of 2024 to 70 at the end of 2025, reflecting growing validation around technology [17] Company Strategy and Development Direction - Innovation is a key strategic differentiator, with a focus on building a durable, world-class life science tools company [8] - The company plans to commercialize a proteoform profiling assay kit in 2027, expanding the utility of its platform for a broader range of proteomics applications [14] - The board of directors has authorized an additional $25 million share repurchase program, reflecting confidence in long-term intrinsic value [32] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing budgetary pressures and uncertainty around NIH funding impacting customer spending decisions [4] - The guidance for 2026 expects revenue to be in the range of $16 million-$18 million, reflecting ongoing pressure on instrument placements and new project funding [34][35] - Management expressed optimism about the potential for revenue growth once the activation energy for customers to shift to the new platform is realized [45] Other Important Information - The company ended the year with approximately $241 million in cash equivalents and investments, sufficient capital to reach cash flow breakeven [33] - A tax benefit preservation plan was adopted to help preserve and protect net operating loss carry-forwards and other tax assets [34] Q&A Session Summary Question: Can you walk us through some of the puts and takes of the quarter? - Management indicated that NIH funding delays impacted customer purchases, leading to lower revenue than expected [40][41] Question: With the momentum seen in 2025, why is growth not expected to be better in 2026? - Management acknowledged the growth in instrument placements but emphasized the need for clear momentum before adjusting revenue projections [43][47] Question: Are there any other factors limiting adoption beyond the funding environment? - Management noted that the evidence from customer data is growing, and the scientific community is recognizing the value of untargeted proteomics [49][51]